TY  - JOUR
AU  - Hennrich, Ute
AU  - Eder, Matthias
TI  - [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
JO  - Pharmaceuticals
VL  - 15
IS  - 10
SN  - 1424-8247
CY  - Basel
PB  - MDPI
M1  - DKFZ-2022-02558
SP  - 1292
PY  - 2022
N1  - #EA:W630#
AB  - In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [177Lu]Lu-PSMA-617 was demonstrated.
KW  - PSMA (Other)
KW  - PluvictoTM (Other)
KW  - [177Lu]Lu-PSMA-617 (Other)
KW  - prostate cancer (Other)
KW  - radioligand therapy (RLT) (Other)
KW  - theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36297404
DO  - DOI:10.3390/ph15101292
UR  - https://inrepo02.dkfz.de/record/182301
ER  -